Composite Interceptive Med-Science   Report issue

For profit
Founded: Bangalore India (2018)

Organization Overview

First Clinical Trial
2018
NCT03503708
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Composite Interceptive Med Science | Composite Interceptive Med-Science | Composite Interceptive Med-Science Laboratories Pvt Ltd

Active Ingredients

Drugs in Other Trials (2)

livitol-70 (1 trial)

prolectin-m (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 2
  • # of Trial APIs: 2